Skip to search formSkip to main contentSkip to account menu

Gynodian

Known as: Androst-5-en-17-one, 3-((1-oxoheptyl)oxy)-, (3beta)-, mixt. with (17beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl pentanoate 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Drug CombinationsEstradioldehydroepiandrosterone
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study.
Review
1990
Review
1990
[Hormone substitution in the female climacteric--goals, means, effects].
Traditional beliefs about climacteric symptoms and widespread imaginations about unwanted effects of estrogens in the pill have… 
1983
1983
Clinical and metabolic effects of Gynodian-depot in vegetoneurotic disorders following removal of uterine myoma in menopausal patients.
1981
1981
Catabolic effects and the influence on hormonal variables under treatment with Gynodian-Depot or dehydroepiandrosterone (DHEA) oenanthate.
1979
1979
SERUM TESTOSTERONE, FSH/LH AND URINARY EXCRETION OF ESTROGENS AND CORTICOIDS DURING TREATMENT WITH AN INJECTABLE, LONGACTING ESTROGEN‐DHEA PREPARATION
Abstract. Ten weeks after total hysterectomy and bilateral salpingo‐oophorectomy, nine women were treated with injections of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)